Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Change in Accured Expenses (2019 - 2025)

Biodesix's Change in Accured Expenses history spans 7 years, with the latest figure at $974000.0 for Q4 2025.

  • For Q4 2025, Change in Accured Expenses fell 42.5% year-over-year to $974000.0; the TTM value through Dec 2025 reached $1.9 million, up 13.56%, while the annual FY2025 figure was $1.9 million, 13.56% up from the prior year.
  • Change in Accured Expenses reached $974000.0 in Q4 2025 per BDSX's latest filing, up from $486000.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $3.3 million in Q2 2023 to a low of -$5.7 million in Q1 2021.
  • Average Change in Accured Expenses over 5 years is -$209450.0, with a median of $338500.0 recorded in 2021.
  • Peak YoY movement for Change in Accured Expenses: plummeted 770.25% in 2021, then skyrocketed 2897.25% in 2023.
  • A 5-year view of Change in Accured Expenses shows it stood at $1.8 million in 2021, then plummeted by 106.91% to -$127000.0 in 2022, then soared by 698.43% to $760000.0 in 2023, then soared by 122.89% to $1.7 million in 2024, then plummeted by 42.5% to $974000.0 in 2025.
  • Per Business Quant, the three most recent readings for BDSX's Change in Accured Expenses are $974000.0 (Q4 2025), $486000.0 (Q3 2025), and $2.3 million (Q2 2025).